1. Home
  2. SGHT vs RENE Comparison

SGHT vs RENE Comparison

Compare SGHT & RENE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SGHT
  • RENE
  • Stock Information
  • Founded
  • SGHT 2011
  • RENE 2021
  • Country
  • SGHT United States
  • RENE United States
  • Employees
  • SGHT N/A
  • RENE N/A
  • Industry
  • SGHT Medical Specialities
  • RENE Blank Checks
  • Sector
  • SGHT Health Care
  • RENE Finance
  • Exchange
  • SGHT Nasdaq
  • RENE Nasdaq
  • Market Cap
  • SGHT 140.1M
  • RENE 153.8M
  • IPO Year
  • SGHT 2021
  • RENE 2022
  • Fundamental
  • Price
  • SGHT $3.03
  • RENE $11.91
  • Analyst Decision
  • SGHT Buy
  • RENE
  • Analyst Count
  • SGHT 7
  • RENE 0
  • Target Price
  • SGHT $3.92
  • RENE N/A
  • AVG Volume (30 Days)
  • SGHT 161.2K
  • RENE 149.6K
  • Earning Date
  • SGHT 05-08-2025
  • RENE 01-01-0001
  • Dividend Yield
  • SGHT N/A
  • RENE N/A
  • EPS Growth
  • SGHT N/A
  • RENE N/A
  • EPS
  • SGHT N/A
  • RENE 0.40
  • Revenue
  • SGHT $78,109,000.00
  • RENE N/A
  • Revenue This Year
  • SGHT N/A
  • RENE N/A
  • Revenue Next Year
  • SGHT $11.17
  • RENE N/A
  • P/E Ratio
  • SGHT N/A
  • RENE $29.60
  • Revenue Growth
  • SGHT N/A
  • RENE N/A
  • 52 Week Low
  • SGHT $2.03
  • RENE $11.22
  • 52 Week High
  • SGHT $8.45
  • RENE $11.95
  • Technical
  • Relative Strength Index (RSI)
  • SGHT 56.13
  • RENE 51.16
  • Support Level
  • SGHT $2.81
  • RENE $11.85
  • Resistance Level
  • SGHT $3.26
  • RENE $11.93
  • Average True Range (ATR)
  • SGHT 0.24
  • RENE 0.01
  • MACD
  • SGHT -0.01
  • RENE -0.00
  • Stochastic Oscillator
  • SGHT 38.57
  • RENE 60.40

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

About RENE Cartesian Growth Corporation II

Cartesian Growth Corp II is a blank check company.

Share on Social Networks: